A Phase 1 interventional study of Tirzepatide and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 2 sites in China. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-07-06.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 42nd largest by enrollment, is one of 5 that started in 2020, is one of 8 in phase 1, and was the 15th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Las Rías Medical Center · Sites in Paraguay
Ages 18–70
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
Matthew J. Budoff · Sites in United States
Ages 40–80
Dr Adnan Agha · Sites in United Arab Emirates
Ages 18–99
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 6 · Phase 3 17 · Phase 4 10
First in 2016; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 160 across the 43 interventional studies. Of the 29 that completed or were terminated, 25 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 43 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 213th largest by enrollment of the 232 interventional ones that give a count, is one of 14 that started in 2020, is one of 76 in phase 1, and was the 157th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing tirzepatide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07438444Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | 2027-07 |
| NCT07588438Las Rías Medical CenterEfficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | 2027-08-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to learn more about the safety and side effects of tirzepatide in Chinese participants with type 2 diabetes mellitus. The study will also measure how much tirzepatide gets into the bloodstream and how long it takes the body to remove it. The study will last about six or eight months for each participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo once weekly (QW) subcutaneously (SC).
Drug: Placebo
Participants in Cohort 1 received weekly SC doses of tirzepatide with titration regimen starting from 2.5 mg for Weeks 0 through 3 followed by 5 mg for Weeks 4 through 7, 7.5 mg for Weeks 8 through 11, and 10 mg for Weeks 12 through 15. Participants in Cohort 2 received weekly SC doses of tirzepatide with titration regimen starting from 2.5 mg for Weeks 0 through 3 followed by 5 mg for Weeks 4 through 7, 7.5 mg for Weeks 8 through 11, and 10 mg for Weeks 12 through 15, 12.5 mg for Weeks 16 through 19, and 15 mg for Weeks 20 through 23.
Drug: Tirzepatide
Administered SC
Also known as: LY3298176
Administered SC
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration.
The number of participants with one or more SAEs is assessed as related to the study drug and is summarized cumulatively. A serious adverse event is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, is reported in the Reported Adverse Events module.
Time frame: Baseline up to 43 Weeks
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to 168 Hour Post-dose (AUC [0-168]) of Tirzepatide (Cohort 1)
PK: AUC \[0-168\] of Tirzepatide.
Time frame: Week 0 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 7 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 15 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose).
PK: AUC [0-168] of Tirzepatide (Cohort 2)
PK: AUC \[0-168\] of Tirzepatide.
Time frame: Week 0 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 7 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 23 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose).
PK: Maximum Concentration (Cmax) of Tirzepatide (Cohort 1)
PK: Cmax of Tirzepatide.
Time frame: Week 0 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 7 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 15 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose).
PK: Cmax of Tirzepatide (Cohort 2)
PK: Cmax of Tirzepatide.
Time frame: Week 0 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 7 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose); Week 23 - (Pre-dose, 8, 24, 48, 72, 168 hours post-dose).
| Milestone | Placebo | Cohort 1 (2.5 to 10 Milligram (mg) Tirzepatide) | Cohort 2 (2.5 to 15 mg Tirzepatide) |
|---|---|---|---|
| Started | 4 | 10 | 10 |
| Received at least one dose of study drug | 4 | 10 | 10 |
| Completed | 3 | 9 | 10 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
The number of participants with one or more SAEs is assessed as related to the study drug and is summarized cumulatively. A serious adverse event is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, is reported in the Reported Adverse Events module.
| participants | Placebo | Cohort 1 (2.5 to 10 Milligram (mg) Tirzepatide) | Cohort 2 (2.5 to 15 mg Tirzepatide) |
|---|---|---|---|
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. | 1 | 0 | 0 |
PK: AUC \[0-168\] of Tirzepatide.
| nanogram hour per milliliter (ng*h/mL) | Cohort 1: 2.5 to 10 mg Tirzepatide |
|---|---|
| Week 0 | 35100 ± 14 |
| Week 7 | 125000 ± 16 |
| Week 15 | 263000 ± 17 |
PK: AUC \[0-168\] of Tirzepatide.
| nanogram hour per milliliter (ng*h/mL) | Cohort 2: 2.5 to 15 mg Tirzepatide |
|---|---|
| Week 0 | 30900 ± 14 |
| Week 7 | 110000 ± 16 |
| Week 23 | 357000 ± 16 |
PK: Cmax of Tirzepatide.
| nanograms per milliliter (ng/mL) | Cohort 1: 2.5 to 10 mg Tirzepatide |
|---|---|
| Week 0 | 306 ± 28 |
| Week 7 | 1030 ± 13 |
| Week 15 | 2200 ± 16 |
PK: Cmax of Tirzepatide.
| nanograms per milliliter (ng/mL) | Cohort 2: 2.5 to 15 mg Tirzepatide |
|---|---|
| Week 0 | 257 ± 17 |
| Week 7 | 915 ± 18 |
| Week 23 | 2930 ± 20 |
Collected over Up To 43 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Cohort 1 (2.5 to 10 Milligram (mg) Tirzepatide) | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Cohort 2 (2.5 to 15 mg Tirzepatide) | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Event | Placebo | Cohort 1 (2.5 to 10 Milligram (mg) Tirzepatide) | Cohort 2 (2.5 to 15 mg Tirzepatide) |
|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/4 | 0/10 | 0/10 |
| Event | Placebo | Cohort 1 (2.5 to 10 Milligram (mg) Tirzepatide) | Cohort 2 (2.5 to 15 mg Tirzepatide) |
|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 0/4 | 5/10 | 8/10 |
| HyperlipidaemiaMetabolism and nutrition disorders | 3/4 | 5/10 | 2/10 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 6/10 | 4/10 |
| Abdominal distensionGastrointestinal disorders | 0/4 | 2/10 | 5/10 |
| Upper respiratory tract infectionInfections and infestations | 2/4 | 0/10 | 0/10 |
| NauseaGastrointestinal disorders | 0/4 | 1/10 | 4/10 |
| Lipase increasedInvestigations | 0/4 | 1/10 | 3/10 |
| Coronary artery diseaseCardiac disorders | 1/4 | 0/10 | 0/10 |
| Tooth lossGastrointestinal disorders | 1/4 | 0/10 | 0/10 |
| Electrocardiogram qt prolongedInvestigations | 1/4 | 0/10 | 0/10 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo | Cohort 1 (2.5 to 10 Milligram (mg) Tirzepatide) | Cohort 2 (2.5 to 15 mg Tirzepatide) | Total |
|---|---|---|---|---|
| Mean | 56.5 ± 7.5 | 55.8 ± 5.2 | 56.8 ± 5.4 | 56.3 ± 5.4 |
| Sex: Female, Male(Participants) | Placebo | Cohort 1 (2.5 to 10 Milligram (mg) Tirzepatide) | Cohort 2 (2.5 to 15 mg Tirzepatide) | Total |
|---|---|---|---|---|
| Female | 1 | 6 | 4 | 11 |
| Male | 3 | 4 | 6 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Cohort 1 (2.5 to 10 Milligram (mg) Tirzepatide) | Cohort 2 (2.5 to 15 mg Tirzepatide) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 4 | 10 | 10 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Cohort 1 (2.5 to 10 Milligram (mg) Tirzepatide) | Cohort 2 (2.5 to 15 mg Tirzepatide) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 4 | 10 | 10 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Cohort 1 (2.5 to 10 Milligram (mg) Tirzepatide) | Cohort 2 (2.5 to 15 mg Tirzepatide) | Total |
|---|---|---|---|---|
| China | 4 | 10 | 10 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2020 to primary completion in Aug 2021, 9 months.
Results were first posted in Jul 2023, 1 year 10 months after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 9 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide